Matrix metalloproteinase inhibitor (ONO-4817) attenuates ischemia-reperfusion injury in rat lung

Medical Science Monitor

Volumn 12, Issue 2, 2006, Pages

  Shimoyama, Takehiko ^a   Tabuchi, Noriyuki ^a   Chung, Jihwa ^b   Koyama, Takatoshi ^b   Sunamori, Makoto ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Ischemia reperfusion; Lung preservation; Lung transplantation

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; CD31 ANTIGEN; GELATINASE A; GELATINASE B; GLYCOPROTEIN P 15095; MATRIX METALLOPROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; DRUG EFFECT; EDEMA; HISTOPATHOLOGY; ISCHEMIA; LUNG ALVEOLUS MACROPHAGE; LUNG INJURY; LUNG INTERSTITIUM; LUNG LAVAGE; LUNG VENTILATION; MALE; NEUTROPHIL; NONHUMAN; RAT; REPERFUSION; REPERFUSION INJURY; TEMPERATURE; TISSUE OXYGENATION;

ANIMALS; ANTIGENS, CD11C; ANTIGENS, CD31; LUNG; MACROPHAGES, ALVEOLAR; MALE; MATRIX METALLOPROTEINASES; NEUTROPHILS; PHENYL ETHERS; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY;

EID: 32044455107     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Aracasoy SM, Kotloff RM: Lung Transplantation. N Eng J Med, 1999; 340: 1081-91
2. Thabut G, Vinatier I, Stern JB et al: Primary Graft Failure Following Lung Transplantation. Predictive Factors of Mortality. Chest, 2002; 121: 1876-82
3. Chatila WM, Furukawa S, Gaughan JP, Criner GJ: Respiratory failure after lung transplantation. Chest, 2003; 123: 165-73
4. Perrot M, Liu M, Weddel K, Keshavjee S: Ischemia-reperfusion-induced lung injury. Am J Crit Care Med, 2003; 167: 490-511
5. Shimoyama T, Tabuchi N, Kojima K et al: Aprotinin attenuated ischemia-reperfusion injury in an isolated rat lung model after 18-hours preservation. Eur J Cardiothorac Surg, 2005; 28: 581-87
6. Yano M, Omoto Y, Yamakawa Y et al: Increased Matrix Metalloproteinase 9 Activity and mRNA Expression in Lung Ischemia-Reperfusion Injury. J Heart Lung Transplant, 2001; 20: 679-86
7. Keck T, Balcom JM, Castillo CF et al: Matrix Metalloproteinase-9 Promotes Neutrophil Migration and Alveolar capillary Leakage in Pancreatitis-Associated Lung Injury in the Rat. Gastroenterology, 2002; 122: 188-201
8. Yamada A, Uegaki A, Nakamura T, Ogawa K: ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pig. Inflamm. Res, 2000; 49: 144-46
9. Kunugi S, Fukuda Y, Ishizaki M, Yamanaka N: Role of MMP-2 in alveolar epithelial cell repair after bleomycin administration in rabbits. Lab Invest, 2001; 81: 1309-18
10. Yurchenco PD, Schittny JC: Molecular architecture of basement membranes. FASEB J, 1990; 4: 1577-90
11. Parks WC, Shapiro SD: Matrix metalloproteinases in lung biology. Respir Res, 2001; 2: 10-19
12. Gibbs DF, Shanley TP, Warner RL et al: Role of matrix metalloproteinases in models of macrophage-dependent acute lung injury. Am J Respir Cell Mol Biol, 1999; 20: 1145-54
13. Owen CA, Hu Z, Barrick B, Shapiro SD: Inducible expression of tissue inhibitor of metalloproteinase-resistant matrix metalloproteinase-9 on the cell surface of neutrophils. Am J Cell Mol Biol, 2003; 29: 283-94
14. Delclaux C, Delacourt C, D'Ortho MP et al: Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol, 1996; 14: 288-95
15. Mackarel AJ, Cottell DC, Russell KJ et al: Migration of neutrophils across human pulmonary endothelial cells is not blocked by matrix metalloproteinase or serine protease inhibitors. Am J Respir Cell Mol Biol, 1999; 20: 1209-19
16. Betsuyaku T, Shipley JM, Liu Z, Senior RM: Neutrophil emigration in the lungs, peritoneum, and skin does not require gelatinase B. Am J Respir Cell Mol Biol, 1999; 20: 1303-9
17. Fisher SM, Tribble CG, Long SM et al: Lung Transplant Reperfusion Injury Involves Pulmonary Macrophages and Circulating Leukocytes in a Biphasic Response. J Thorac Cardiovasc Surg, 2001; 121: 1069-75
18. Naidu BV, Krishnadasan B, Farivar AS et al: Early activation of the alveolar macrophage is critical to the development of lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg, 2003; 126: 200-7
19. Rizzo M, SivaSai KS, Smith MA et al: Increased expression of inflammatory cytokines and adhesion moleclules by alveolar macrophages of human lung allograft recipients with acute rejection: Decline with resolution of rejection. J Heart Lung Transplant, 2000; 19: 858-65
20. Liang C, Wu Z, Ding J et al: Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages. Acta Pharmacol Sin, 2004; 25: 1426-32
21. Sakata Y, Yamamoto K, Mano T et al: Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats. Its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation, 2004; 109: 2143-49
22. Kim HS, Shang T, Chen Z et al: TGF-β1 stimulates production of gelatinase (MMP-9), collagenases (MMP-1, -13) and stromelysins (MMP-3, -10, -11) by human corneal epithelial cells. Exp Eye Res, 2004; 79: 263-74
23. Yamamoto A, Yano S, Shiraga M et al: A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Int J Cancer, 2003; 103: 822-28
24. Muraishi Y, Mitani N, Fuse H, Saiki I: Effect of a matrix metalloproteinase inhibitor (ONO-4817) on lung metastasis of murine renal cell carcinoma. Anticancer Res, 2001; 21: 3845-52
25. Soccal PM, Gasche Y, Miniati DN et al: Matrix metalloproteinase inhibition decreases ischemia-reperfusion injury after lung transplantation. Am J Transplant, 2004; 4: 41-50